Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 1, 2019
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Acne vulgaris is a highly prevalent dermatologic disorder that affects up to 90% percent of the population at some point in their lives to varying degrees. Acne scarring is an unfortunate complication of the inflammation that results if acne is not sufficiently treated. Classically, acne scarring has been described as either atrophic, hypertrophic, keloidal, or pigmented. Atrophic is by far the most common type of acne scarring and is subdivided into boxcar, rolling, and icepick subtypes. The presence of acne scarring has been associated with a significant decrease in patient well-being and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All gender patients
- • Age older than 18 years
- • Fitzpatrick skin types I-III
- • Facial acne scarring of grades III-IV
- • Both sides of the face should have similar amount and severity of acne scarring
- Exclusion Criteria:
- • History of keloidal scarring
- • Localized or active infection in the treatment region
- • Immunodeficiency disorders
- • Porphyria or light sensitivity
- • Connective tissue disorders.
- • Pregnant or nursing
- • Recent isotretinoin use within the past 6 months
- • Renal Disease
- • Allergies to lidocaine, tetracaine, valacyclovir
Trial Officials
Mathew Avram, MD
Principal Investigator
Massachusetts General Hospital
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials